Puma Biotechnology (PBYI) Other Non-Current Liabilities (2019 - 2025)
Puma Biotechnology's (PBYI) quarterly Other Non-Current Liabilities came in at $1.8 million in Q1 2025, up 1357.02% YoY from $121000.0 in Q1 2024, and up 1357.02% on a QoQ basis from $121000.0 in Q4 2024.
Puma Biotechnology (PBYI) Other Non-Current Liabilities (2019 - 2025) Analysis & Trends
Puma Biotechnology (PBYI) has 7 years of Other Non-Current Liabilities data on file, last reported at $1.8 million in Q1 2025.
- Quarterly Other Non-Current Liabilities rose 1357.02% year-over-year to $1.8 million in Q1 2025, while the trailing twelve-month figure through Mar 2025 was $1.8 million (up 1357.02% YoY) and the FY2024 annual result came in at $121000.0, changed 0.0% from the prior year.
- Other Non-Current Liabilities climbed to $1.8 million in Q1 2025, from $121000.0 in the prior quarter.
- In the past five years, Other Non-Current Liabilities ranged from a high of $7.6 million in Q2 2023 to a low of $37000.0 in Q3 2022.
- A 5-year average of $2.4 million and a median of $756000.0 in 2022 frame the typical range for Other Non-Current Liabilities.
- Annual changes were most pronounced in 2021 — Other Non-Current Liabilities surged 16178.38% — and 2022, when it slumped 99.39%.
- Tracing PBYI's Other Non-Current Liabilities over 5 years: stood at $5.5 million in 2021, then tumbled by 99.32% to $37000.0 in 2022, then jumped by 227.03% to $121000.0 in 2023, then changed by 0.0% to $121000.0 in 2024, then surged by 1357.02% to $1.8 million in 2025.
- The last three Other Non-Current Liabilities figures came in at $1.8 million (Q1 2025), $121000.0 (Q4 2024), and $121000.0 (Q3 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Puma Biotechnology | 451.24 Mn | 357.33 Mn | 44.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 230,000.00 |
| Mar 31, 2025 | 1.76 Mn |
| Dec 31, 2024 | 121,000.00 |
| Sep 30, 2024 | 121,000.00 |
| Jun 30, 2024 | 3.98 Mn |
| Mar 31, 2024 | 121,000.00 |
| Dec 31, 2023 | 121,000.00 |
| Sep 30, 2023 | 121,000.00 |
| Jun 30, 2023 | 7.57 Mn |
| Mar 31, 2023 | 7.48 Mn |
| Dec 31, 2022 | 37,000.00 |
| Sep 30, 2022 | 37,000.00 |
| Jun 30, 2022 | 5.38 Mn |
| Mar 31, 2022 | 756,000.00 |
| Dec 31, 2021 | 5.46 Mn |
| Sep 30, 2021 | 6.02 Mn |
| Jun 30, 2021 | 1.18 Mn |
| Mar 31, 2021 | 206,000.00 |
| Dec 31, 2020 | 6.38 Mn |
| Sep 30, 2020 | 37,000.00 |